AAAAAA
Results:
1-19
|
Results: 19
Authors:
Gitlitz, BJ
Hoffman, DMJ
Moldawer, N
Belldegrun, A
Figlin, RA
Citation: Bj. Gitlitz et al., Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients, CANCER J, 7(2), 2001, pp. 112-120
Authors:
Zisman, A
Pantuck, AJ
Dorey, F
Said, JW
Shvarts, O
Quintana, D
Gitlitz, BJ
deKernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Improved prognostication of renal cell carcinoma using an integrated staging system, J CL ONCOL, 19(6), 2001, pp. 1649-1657
Authors:
Zisman, A
Pantuck, AJ
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Validation of the UCLA integrated staging system for patients with renal cell carcinoma, J CL ONCOL, 19(17), 2001, pp. 3792-3793
Authors:
Khuri, FR
Rigas, JR
Figlin, RA
Gralla, RJ
Shin, DM
Munden, R
Fox, N
Huyghe, MR
Kean, Y
Reich, SD
Hong, WK
Citation: Fr. Khuri et al., Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer, J CL ONCOL, 19(10), 2001, pp. 2626-2637
Authors:
Goldman, DP
Schoenbaum, ML
Potosky, AL
Weeks, JC
Berry, SH
Escarce, JJ
Weidmer, BA
Kilgore, ML
Wagle, N
Adams, JL
Figlin, RA
Lewis, JH
Cohen, J
Kaplan, R
McCabe, M
Citation: Dp. Goldman et al., Measuring the incremental cost of clinical cancer research, J CL ONCOL, 19(1), 2001, pp. 105-110
Authors:
Pantuck, AJ
Belldegrun, AS
Figlin, RA
Citation: Aj. Pantuck et al., Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma, N ENG J MED, 345(23), 2001, pp. 1711-1712
Authors:
Zisman, A
Pantuck, AJ
Chao, D
Dorey, F
Said, JW
Gitlitz, BJ
de Kernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. Better correlates with clinicaloutcome, J UROL, 166(1), 2001, pp. 54-58
Authors:
Figlin, RA
Citation: Ra. Figlin, Renal cell carcinoma: Current status and future plans, CA J SCI AM, 6, 2000, pp. S52-S54
Authors:
Belldegrun, A
Shvarts, O
Figlin, RA
Citation: A. Belldegrun et al., Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma, CA J SCI AM, 6, 2000, pp. S88-S92
Authors:
Hoffman, DMJ
Figlin, RA
Citation: Dmj. Hoffman et Ra. Figlin, Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex, WORLD J URO, 18(2), 2000, pp. 152-156
Authors:
Hoffman, DMJ
Gitlitz, BJ
Belldegrun, A
Figlin, RA
Citation: Dmj. Hoffman et al., Adoptive cellular therapy, SEMIN ONCOL, 27(2), 2000, pp. 221-233
Authors:
Tsui, KH
Shvarts, O
Smith, RB
Figlin, RA
deKernion, JB
Belldegrun, A
Citation: Kh. Tsui et al., Prognostic indicators for renal cell carcinoma: A multivariate analysis of643 patients using the revised 1997 TNM staging criteria, J UROL, 163(4), 2000, pp. 1090-1095
Authors:
Roth, MD
Gitlitz, BJ
Kiertscher, SM
Park, AN
Mendenhall, M
Moldawer, N
Figlin, RA
Citation: Md. Roth et al., Granulocyte macrophage colony-stimulating factor and interleukin 4 enhancethe number and antigen-presenting activity of circulating CD14(+) and CD83(+) cells in cancer patients, CANCER RES, 60(7), 2000, pp. 1934-1941
Authors:
Elias, L
Lew, D
Figlin, RA
Flanigan, RC
Thompson, ME
Triozzi, PL
Belt, RJ
Wood, DP
Rivkin, SE
Crawford, ED
Citation: L. Elias et al., Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma - A southwest oncology group phase II study, CANCER, 89(3), 2000, pp. 597-603
Authors:
Gitlitz, BJ
Belldegrun, AS
Figlin, RA
Citation: Bj. Gitlitz et al., Adoptive immunotherapy in renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 359-379
Authors:
Figlin, RA
Thompson, JA
Bukowski, RM
Vogelzang, NJ
Novick, AC
Lange, P
Steinberg, GD
Belldegrun, AS
Citation: Ra. Figlin et al., Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2521-2529
Authors:
Yang, HH
Rosove, MH
Figlin, RA
Citation: Hh. Yang et al., Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, AM J HEMAT, 62(4), 1999, pp. 247-250
Authors:
Reissmann, PT
Koga, H
Figlin, RA
Holmes, EC
Salmon, DJ
Citation: Pt. Reissmann et al., Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer, J CANC RES, 125(2), 1999, pp. 61-70
Authors:
Figlin, RA
Citation: Ra. Figlin, Renal cell carcinoma: Management of advanced disease, J UROL, 161(2), 1999, pp. 381-386
Risultati:
1-19
|